What should I avoid while taking Yohimbine 5mg tablets?

Take with or without food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Yohimbine 5mg tablets?

Yohimbine 5mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Yohimbine 5mg tablets?

Yohimbine 5mg tablets is the generic name. It is available under brand names including: Prowess Plain 5mg tablets, Yohimbine 5mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Yohimbine 5mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

5mg

Oral

A plant alkaloid with alpha-2-adrenergic blocking activity.

Active ingredients:

Yohimbine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 07.04.05

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC G04BE04

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Yohimbine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Yohimbine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Yohimbine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

2 branded products available

2 productsShow details

Part of the Prowess brand family (generic: Yohimbine)

2 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Yohimbine on the MHRA register

Yohimbine 5mg tablets

Special Order

None

Special

Prowess Plain 5mg tablets

Harley Street Supplies Ltd

None

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

15 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Sildenafil 50mg orodispersible films sugar free

Other

50mg

Same therapeutic group

Sildenafil 75mg orodispersible films sugar free

Other

75mg

Same therapeutic group

Sildenafil 100mg orodispersible films sugar free

Other

100mg

Same therapeutic group

Sildenafil 12.5mg/dose oromucosal spray sugar free

Spray

12.5mg

Same therapeutic group

Sildenafil 20mg/5ml oral suspension

Oral suspension

20mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Yohimbine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Yohimbine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

4246511000001102

dm+d ID

4246511000001102

VTM (Virtual Therapeutic Moiety)

777964009

VMP (Virtual Medicinal Product)

4246511000001102

BNF code

07040500

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

G04BE04

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

19 found

Half-life

36 minutes

Mechanism

Yohimbine is a pre-synaptic alpha 2-adrenergic blocking agent.

Food interactions

1 warning

Human targets

12 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

7 to 87%

Rapidly absorbed following oral administration. Bioavailability is highly variable, ranging from 7 to 87% (mean 33%).

Half-life

36 minutes

Elimination half-life is approximately 36 minutes.

Metabolism

Yohimbine appears to undergo extensive metabolism in an organ of high flow such as the liver or kidney, however, the precise metabolic fate of yohimbine has not been fully determined.…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Vet approved

Withdrawn

Small molecule

About this compound

A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.

Properties:

solid

Avg. mass: 354.44 Da

DrugBank indication

Indicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.

Also known as(112)

(+)-yohimbine

(16α,17α)-17-hydroxyyohimban-16-carboxylic acid methyl ester

17α-hydroxyyohimban-16α-carboxylic acid methyl ester

Johimbin

Quebrachin

Yohimbic acid methyl ester

Yohimbin

Yohimbine

Dosage forms(5)

Tablet (Oral) — 2 mg

Tablet (Oral) — 5.4 mg

Tablet (Oral) — 6 mg

Tablet, sugar coated (Oral) — 5 mg

Tablet (Oral) — 5 mg

Molecular properties(19)

Drug interactions(1324)

Known interactions with other medications. Always consult a healthcare professional.

Valsartan

Moderate

DB00177

Yohimbine may decrease the antihypertensive activities of Valsartan.

Check this interaction

Ramipril

Moderate

DB00178

Yohimbine may decrease the antihypertensive activities of Ramipril.

Check this interaction

Esmolol

Moderate

DB00187

Yohimbine may decrease the antihypertensive activities of Esmolol.

Check this interaction

Betaxolol

Moderate

DB00195

Yohimbine may decrease the antihypertensive activities of Betaxolol.

Check this interaction

Remikiren

Moderate

DB00212

Yohimbine may decrease the antihypertensive activities of Remikiren.

Check this interaction

Torasemide

Moderate

DB00214

Yohimbine may decrease the antihypertensive activities of Torasemide.

Check this interaction

Bethanidine

Moderate

DB00217

Yohimbine may decrease the antihypertensive activities of Bethanidine.

Check this interaction

Guanadrel

Moderate

DB00226

Yohimbine may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Yohimbine may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Chlorthalidone

Moderate

DB00310

Yohimbine may decrease the antihypertensive activities of Chlorthalidone.

Check this interaction

Nitroprusside

Moderate

DB00325

Yohimbine may decrease the antihypertensive activities of Nitroprusside.

Check this interaction

Atenolol

Moderate

DB00335

Yohimbine may decrease the antihypertensive activities of Atenolol.

Check this interaction

Minoxidil

Moderate

DB00350

Yohimbine may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Treprostinil

Moderate

DB00374

Yohimbine may decrease the antihypertensive activities of Treprostinil.

Check this interaction

Bendroflumethiazide

Moderate

DB00436

Yohimbine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Fosinopril

Moderate

DB00492

Yohimbine may decrease the antihypertensive activities of Fosinopril.

Check this interaction

Trandolapril

Moderate

DB00519

Yohimbine may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Metolazone

Moderate

DB00524

Yohimbine may decrease the antihypertensive activities of Metolazone.

Check this interaction

Benazepril

Moderate

DB00542

Yohimbine may decrease the antihypertensive activities of Benazepril.

Check this interaction

Enalapril

Moderate

DB00584

Yohimbine may decrease the antihypertensive activities of Enalapril.

Check this interaction

Cyclothiazide

Moderate

DB00606

Yohimbine may decrease the antihypertensive activities of Cyclothiazide.

Check this interaction

Candoxatril

Moderate

DB00616

Yohimbine may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Guanabenz

Moderate

DB00629

Yohimbine may decrease the antihypertensive activities of Guanabenz.

Check this interaction

Mecamylamine

Moderate

DB00657

Yohimbine may decrease the antihypertensive activities of Mecamylamine.

Check this interaction

Moexipril

Moderate

DB00691

Yohimbine may decrease the antihypertensive activities of Moexipril.

Check this interaction

Phentolamine

Moderate

DB00692

Yohimbine may decrease the antihypertensive activities of Phentolamine.

Check this interaction

Lisinopril

Moderate

DB00722

Yohimbine may decrease the antihypertensive activities of Lisinopril.

Check this interaction

Nitroglycerin

Moderate

DB00727

Yohimbine may decrease the antihypertensive activities of Nitroglycerin.

Check this interaction

Hydroflumethiazide

Moderate

DB00774

Yohimbine may decrease the antihypertensive activities of Hydroflumethiazide.

Check this interaction

Cryptenamine

Moderate

DB00785

Yohimbine may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Perindopril

Moderate

DB00790

Yohimbine may decrease the antihypertensive activities of Perindopril.

Check this interaction

Candesartan cilexetil

Moderate

DB00796

Yohimbine may decrease the antihypertensive activities of Candesartan cilexetil.

Check this interaction

Tolazoline

Moderate

DB00797

Yohimbine may decrease the antihypertensive activities of Tolazoline.

Check this interaction

Eprosartan

Moderate

DB00876

Yohimbine may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Chlorothiazide

Moderate

DB00880

Yohimbine may decrease the antihypertensive activities of Chlorothiazide.

Check this interaction

Quinapril

Moderate

DB00881

Yohimbine may decrease the antihypertensive activities of Quinapril.

Check this interaction

Omapatrilat

Moderate

DB00886

Yohimbine may decrease the antihypertensive activities of Omapatrilat.

Check this interaction

Phenoxybenzamine

Moderate

DB00925

Yohimbine may decrease the antihypertensive activities of Phenoxybenzamine.

Check this interaction

Telmisartan

Moderate

DB00966

Yohimbine may decrease the antihypertensive activities of Telmisartan.

Check this interaction

Methyldopa

Moderate

DB00968

Yohimbine may decrease the antihypertensive activities of Methyldopa.

Check this interaction

Hydrochlorothiazide

Moderate

DB00999

Yohimbine may decrease the antihypertensive activities of Hydrochlorothiazide.

Check this interaction

Trichlormethiazide

Moderate

DB01021

Yohimbine may decrease the antihypertensive activities of Trichlormethiazide.

Check this interaction

Deserpidine

Moderate

DB01089

Yohimbine may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Pentolinium

Moderate

DB01090

Yohimbine may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Yohimbine may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Diazoxide

Moderate

DB01119

Yohimbine may decrease the antihypertensive activities of Diazoxide.

Check this interaction

Bretylium

Moderate

DB01158

Yohimbine may decrease the antihypertensive activities of Bretylium.

Check this interaction

Terazosin

Moderate

DB01162

Yohimbine may decrease the antihypertensive activities of Terazosin.

Check this interaction

Rescinnamine

Moderate

DB01180

Yohimbine may decrease the antihypertensive activities of Rescinnamine.

Check this interaction

Captopril

Moderate

DB01197

Yohimbine may decrease the antihypertensive activities of Captopril.

Check this interaction

Showing 50 of 1324 interactions

Food & lifestyle interactions

Advice

Take with or without food.

How it works

Mechanism of action

Yohimbine is a pre-synaptic alpha 2-adrenergic blocking agent. The exact mechanism for its use in impotence has not been fully elucidated. However, yohimbine may exert its beneficial effect on erectile ability through blockade of central alpha 2-adrenergic receptors producing an increase in sympathetic drive secondary to an increase in norepinephrine release and in firing rate of cells in the brain noradrenergic nuclei. Yohimbine-mediated norepinephrine release at the level of the corporeal tissues may also be involved. In addition, beneficial effects may involve other neurotransmitters such as dopamine and serotonin and cholinergic receptors.

Pharmacodynamics

Yohimbine is an indolalkylamine alkaloid with chemical similarity to reserpine. Yohimbine blocks presynaptic alpha-2 adrenergic receptors. Its action on peripheral blood vessels resembles that of reserpine, though it is weaker and of short duration. Yohimbine's peripheral autonomic nervous system effect is to increase parasympathetic (cholinergic) and decrease sympathetic (adrenergic) activity. It is to be noted that in male sexual performance, erection is linked to cholinergic activity and to alpha-2 adrenergic blockade which may theoretically result in increased penile inflow, decreased penile outflow or both. Yohimbine exerts a stimulating action on the mood and may increase anxiety. Such actions have not been adequately studied or related to dosage although they appear to require high doses of the drug. Yohimbine has a mild anti-diuretic action, probably via stimulation of hypothalmic center and release of posterior pituitary hormone. Reportedly Yohimbine exerts no significant influence on cardiac stimulation and other effects mediated by (beta)-adrenergic receptors. Its effect on blood pressure, if any, would be to lower it; however, no adequate studies are at hand to quantitate this effect in terms of Yohimbine dosage.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Rapidly absorbed following oral administration. Bioavailability is highly variable, ranging from 7 to 87% (mean 33%).

Half-life

Elimination half-life is approximately 36 minutes.

Metabolism

Yohimbine appears to undergo extensive metabolism in an organ of high flow such as the liver or kidney, however, the precise metabolic fate of yohimbine has not been fully determined.

Drug targets(12)

Proteins and enzymes this drug interacts with in the body

Alpha-2A adrenergic receptor

BE0000289

ADRA2A

antagonist

Specific functionalpha-1B adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol

Alpha-2B adrenergic receptor

BE0000572

ADRA2B

antagonist

Specific functionalpha2-adrenergic receptor activity

Cellular location

Cell membrane

General function & pharmacology

Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol

Alpha-2C adrenergic receptor

BE0000342

ADRA2C

antagonist

Specific functionalpha-2A adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins

5-hydroxytryptamine receptor 1A

BE0000291

HTR1A

partial agonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:37935376 PMID:37935377 PMID:8138923 PMID:8393041

Also functions as a receptor for various drugs and psychoactive substances .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:38552625 PMID:8138923 PMID:8393041

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:8138923 PMID:8393041

HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores .
PMID:33762731 PMID:35610220
Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the response to anxiogenic stimuli PMID:18476671 PMID:20363322 PMID:20945968

5-hydroxytryptamine receptor 1B

BE0000797

HTR1B

partial agonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD) .
PMID:23519210 PMID:23519215 PMID:29925951

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

HTR1B is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity .
PMID:29925951 PMID:35610220
Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:29925951
Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior .
PMID:18476671 PMID:20945968
Besides, plays a role in vasoconstriction of cerebral arteries PMID:15853772

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2D6Cytochrome P450 2D6

substrate

CYP3A4Cytochrome P450 3A4

substrate

Scientific references(1)

Holmes A., Quirk G.J.

Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine.

Trends in Pharmacological Sciences

2010 Jan31(1):2-7. doi: 10.1016/j.tips.2009.10.003. Epub 2009 Dec 28

PMID: 20036429 DOI: 10.1016/j.tips.2009.10.003

ATC classification(1 code)

ATC G04BE04

Affected organisms(1)

Humans and other mammals

International brands(12)

Salt forms(1)

Yohimbine hydrochloride(DBSALT001153)

Experimental properties(2)

External resources(3)

RxList PDRhealth Drugs.com

Commercial products(9)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Yohimbine

DB01392

CAS number

146-48-5

UNII (FDA)

2Y49VWD90Q

InChI Key (molecular fingerprint)

BLGXFZZNTVWLAY-SCYLSFHTSA-N

Additional database identifiers

Drugs Product Database (DPD)

20371

Drugs Product Database (DPD)

6681

ChEBI

10093

PubChem Compound

8969

PubChem Substance

46504602

KEGG Compound

C09256

ChemSpider

8622

BindingDB

50013515

PharmGKB

PA451946

Therapeutic Targets Database

DAP000087

Wikipedia

Yohimbine

ChEMBL

CHEMBL15245

ZINC

ZINC000003860825

RxCUI

220982

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5287

GenAtlas

HTR1B

GeneCards

HTR1B

GenBank Gene Database

D10995

GenBank Protein Database

219679

IUPHAR

Guide to Pharmacology

UniProtKB

P28222

UniProt Accession

5HT1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5289

GenAtlas

HTR1D

GeneCards

HTR1D

GenBank Gene Database

M89955

GenBank Protein Database

177772

IUPHAR

Guide to Pharmacology

UniProtKB

P28221

UniProt Accession

5HT1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6255

GenAtlas

KCNJ1

GeneCards

KCNJ1

GenBank Gene Database

U12541

GenBank Protein Database

529313

IUPHAR

429

Guide to Pharmacology

429

UniProtKB

P48048

UniProt Accession

KCNJ1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6256

GeneCards

KCNJ10

Guide to Pharmacology

438

UniProtKB

P78508

UniProt Accession

KCJ10_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6257

GenAtlas

KCNJ11

GeneCards

KCNJ11

GenBank Gene Database

D50582

GenBank Protein Database

1088445

IUPHAR

442

UniProtKB

Q14654

UniProt Accession

KCJ11_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6258

GenAtlas

KCNJ12

GeneCards

KCNJ12

GenBank Gene Database

L36069

GenBank Protein Database

567019

IUPHAR

431

Guide to Pharmacology

431

UniProtKB

Q14500

UniProt Accession

KCJ12_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6260

GeneCards

KCNJ14

Guide to Pharmacology

433

UniProtKB

Q9UNX9

UniProt Accession

KCJ14_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6261

GeneCards

KCNJ15

UniProtKB

Q99712

UniProt Accession

KCJ15_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6269

GenAtlas

KCNJ8

GeneCards

KCNJ8

GenBank Gene Database

D50312

IUPHAR

441

UniProtKB

Q15842

UniProt Accession

KCNJ8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5294

GenAtlas

HTR2B

GeneCards

HTR2B

GenBank Gene Database

X77307

GenBank Protein Database

475198

IUPHAR

Guide to Pharmacology

UniProtKB

P41595

UniProt Accession

5HT2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

International reference pricing

3 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.96/tablet

To $22.80/g

Yocon 5.4 mg tablet

$0.96/tablet

Yohimbine 5.4 mg tablet

$1.04/tablet

Yohimbine hcl powder

$22.80/g

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Yohimbine 5mg tablets

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science
14

Chemical identifiers

Yohimbine

Additional database identifiers

International reference pricing

DrugBank citations

Yohimbine 5mg tablets

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science14

Chemical identifiers

Yohimbine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
14